MicroPort® NeuroTech（Shanghai）Co., Ltd.

News

2022-03-01

MicroPort NeuroTech™ Receives NMPA Marketing Approval for its Diveer^® Intracranial Balloon Catheter

MicroPort NeuroTech Limited has received marketing approval from China’s National Medical Products Administration (NMPA) for its independently-developed Diveer^® Intracranial Balloon Catheter (Diveer^® ).
2022-01-19

MicroPort NeuroTech™ Bridge^® Vertebral Drug-Eluting Stent Presents in Frontiers in Neurology with PESS Results

Shanghai, China, 20 December 2021 — MicroPort NeuroTech Limited (MicroPort NeuroTech™) has published the outcomes of the study ‘Prospective Evaluation of Safety and Efficacy Vertebral Drug-eluting Stent System (PESS),’ a pre-market clinical trial for the Bridge® Rapamycin Target Eluting Vertrbral Stent System (Bridge®, previously known as Firehorus).
2022-01-19

MicroPort^® NeuroTech Obtains KGMP Certification

Seoul, South Korea, 26 November — MicroPort NeuroTech (Shanghai) Co., Ltd. (MicroPort® NeuroTech) recently received the Korea Good Manufacturing Practice (KGMP) certification, a quality system standard for medical devices in South Korea, following a review by the Ministry of Food and Drug Safety of Korea (MFDS). This certification further signals that MicroPort® NeuroTech has established a world-leading quality management system, as it follows the securement of various system certifications, including ISO13485:2016 and the ANVISA certification by the Brazilian National Health Surveillance Agency.
2022-01-18

MicroPort^® NeuroTech Completes Strategic Financing with Shareholder Structure Optimization, as Foundation for Next-Step Global Expansion

Shanghai, China, 11 November 2021 - MicroPort NeuroTech Limited (MicroPort^® NeuroTech), a subsidiary of MicroPort Scientific Corporation (MicroPort®) that focusses on the development and promotion of innovative therapeutic solutions for cerebrovascular diseases, successfully entered a financing agreement of US$ 150 million in amount as planned, which brought to NeuroTech several renowned strategic investors including CICC Capital, HHF Capital, Broad Vision Funds, Runkun Partners and Prosperous Alliance.
2022-01-17

MicroPort^® NeuroTech NUMEN Coil Embolization System Approved for Market in Korea

Seoul, Republic of Korea, 10 September 2021 — The NUMEN^® Coil Embolization System (NUMEN^®) and NUMEN FR^® Detachment System (NUMEN FR^®), developed by MicroPort NeuroTech (Shanghai) Co., Ltd.
2021-11-27

MicroPort^® NeuroTech NUMEN™ Coil Products Showcased at Shaolin Neurosurgical Conference

Zhengzhou, China, November 27, 2020 — MicroPort^® NeuroTech recently participated in the 3rd Shaolin International Neurosurgical Conference, part of the 6th Central China Cerebrovascular Disease Forum.
2021-11-04

MicroPort^® NeuroTech Participates in 2021 OCIN as Tubridge^® Used in Over 5,000 Clinical Cases

Shanghai, China, 4 November 2021 — Shanghai MicroPort NeuroTech Co., Ltd. (MicroPort® NeuroTech) recently participated in the 2021 Oriental Conference of Interventional Neurovascology (OCIN) and the Annual Meeting of Shanghai Medical Association Stroke Society, holding a session to mark the milestone of the Tubridge® Flow-diverting Stent (Tubridge®) being used in 5,000 clinical cases.
2021-07-21

MicroPort^® NeuroTech Presents Two New Products at the 7th CSA Annual Academic Conference

Beijing, China, 20 July 2021 — MicroPort^® NeuroTech (Shanghai) Co., Ltd. (MicroPort^® NeuroTech) recently held a national launch of the Rapamycin Target Eluting Vertebral Stent System and Intracranial Support Catheter.
2021-05-29

MicroPort^® NeuroTech Numen^® System and Controller Receive CE Mark

Shanghai, China, 24 May 2021 —The Numen^® Coil Embolization System (Numen^®) and Numen FR^® Coil Detachment System (Numen FR^®), developed by MicroPort NeuroTech (Shanghai) Co., Ltd.
2021-05-03

MicroPort^® NeuroTech Closes Equity Investment in Rapid Medical, Becoming the Largest Shareholder

Shanghai, China—Shanghai MicroPort^® NeuroTech Co., Ltd. (“MicroPort^® NeuroTech”), a subsidiary of MicroPort Scientific Corporation (00853.HK), has recently closed an equity investment deal with Rapid Medical.

1 2 3

上一页 2/3 下一页

手机：

(86)19542912295

电话：

(86) (21)38954600-55200

地址：

1661 Zhangdong Road, Zhangjiang High-tech Park, Pudong New District, Shanghai, PRC

传真：

(21) 50801305

关于我们

患者关怀

投资者关系

人才中心

新闻资讯

|

Copyright 2019 MicroPort® NeuroTech（Shanghai）Co., Ltd. 沪ICP备19033024号-1 微信图片_20200506140817.png 沪公网安备 31011502014931号